2020 Washington Medical Licensure Program

 
Enter your answers for ALL educational activities you intend to earn credit for. Then tap Check Answers at the bottom of the page. If you have already completed a course for this program and wish to complete additional courses at this time, please scan and send your information/answers via email to support@cme.edu or fax to 1-800-647-1356.

Show Test Questions

Hide Test Questions

Self-Assessment Answers for Section 1: Suicide Assessment & Prevention
1 . In 2017, what was the rank of suicide as a cause of death in the United States?
A.
B.
C.
D.
0
2 . About how much higher is the suicide rate among Veterans as compared to the non-Veteran population?
A.
B.
C.
D.
0
3 . The three levels of strategies for suicide prevention are _________, _________, and ____________.
A.
B.
C.
D.
0
4 . What is the name of the conceptual model that frames suicide risk as a balance between protective factors and risk factors at different levels?
A.
B.
C.
D.
0
5 . Which of the following is a tenet of the Patient-Centered Care model for suicide prevention?
A.
B.
C.
D.
0
6 . What is one of the advantages of adopting a Patient-Centered Care model of suicide prevention?
A.
B.
C.
D.
0
7 . Which of the following is a true statement about suicide risk?
A.
B.
C.
D.
0
8 . Which of the following is a true statement about suicide risk in Veteran and non-Veteran populations?
A.
B.
C.
D.
0
9 . Which of the following is a direct warning sign of acute suicide risk?
A.
B.
C.
D.
0
10 . Which of the following is true about asking patients about suicide or suicidal thinking?
A.
B.
C.
D.
0
11 . When attempting to elicit suicidal ideation from a patient, it is best if clinicians ________________?
A.
B.
C.
D.
0
12 . What would be an appropriate course of action for a patient determined to be at an intermediate level of acute suicide risk?
A.
B.
C.
D.
0
13 . Which non-pharmacological treatment modality has been shown to reduce the risk of suicide attempts by helping patients identify and change problematic thinking and behavioral patterns?
A.
B.
C.
D.
0
14 . Which non-pharmacological treatment modality focuses on helping patients cope with stressful life experiences by actively working on difficulties?
A.
B.
C.
D.
0
15 . Which pharmacological therapy has been shown to improve acute suicidal symptoms for up to a week after only a single dose?
A.
B.
C.
D.
0
16 . Which pharmacological therapy has been shown to reduce suicidal behaviors in patients with schizophrenia or schizoaffective disorder?
A.
B.
C.
D.
0
17 . What post-acute care modality has been shown to reduce the rate of suicide death following a psychiatric hospitalization for suicidal ideation/attempt?
A.
B.
C.
D.
0
18 . Which therapeutic modality may allow treatment for suicidal thoughts and behaviors regardless of geographic location or access to traditional care facilities?
A.
B.
C.
D.
0
19 . Which kind of suicide-prevention initiative has not been found to improve population-level suicide rates, either in the general U.S. population or among Veterans?
A.
B.
C.
D.
0
20 . In an effort to dispel stigma and foster a culture of support throughout the Department of Defense, which policy has been put into place?
A.
B.
C.
D.
0
Self-Assessment Answers for Section 2: Pharmacological and Non-Pharmacological Options for Pain Management
21 . Which of the following is not an example of multimodal therapy for acute pain?
A.
B.
C.
D.
0
22 . Non-pharmacologic methods for treating acute pain are appropriate for which phase of healing?
A.
B.
C.
D.
0
23 . Which non-opioid drug, or drug class, has been successfully used to treat acute pain associated with sickle cell crises, renal colic, and trauma?
A.
B.
C.
D.
0
24 . Which phrase best characterizes the evidence base for acupuncture as a pain treatment for chronic pain?
A.
B.
C.
D.
0
25 . Which non-drug approach can ease pain and provide durable relief for some patients with chronic pain conditions?
A.
B.
C.
D.
0
26 . Which class of non-opioid medications can be effective for treating neuropathic pain?
A.
B.
C.
D.
0
27 . Long-acting (LA) and extended-release (ER) formulations of opioids should not be used for __________________?
A.
B.
C.
D.
0
28 . Which statement best describes the efficacy of different opioid analgesic products for treating acute pain?
A.
B.
C.
D.
0
29 . What is a potential limitation of using methadone in the treatment of patients with OUD?
A.
B.
C.
D.
0
30 . What is one potential benefit of the fact that buprenorphine is a partial agonist at opioid receptors compared to methadone?
A.
B.
C.
D.
0